You are here

Recent Pfizer Press Releases

11/7/16 6:45am EST
Pfizer to Present Additional Research For XELJANZ® (Tofacitinib Citrate) In Rheumatologic Diseases, Including Rheumatoid Arthritis and Psoriatic Arthritis

Results of Phase 3 Studies for Investigational XELJANZ for Psoriatic Arthritis to be Presented at 2016 ACR/ARHP Annual Meeting

Twenty Presentations at 2016 ACR/ARHP Annual Meeting Reinforce Pfizer’s Leadership in Inflammation and Immunology

Pfizer Inc. (NYSE:PFE) announced today that 20 abstracts for XELJANZ® (tofacitinib citrate) will be presented at the upcoming 2016 ACR/ARHP Annual Meeting (November 11-16, Washington, DC). Notably, results from the two pivotal Phase 3 OPAL (Oral Psoriatic Arthritis TriaL) studies of tofacitinib – the only Janus kinase (JAK) inhibitor under investigation for psoriatic arthritis (PsA) – will be presented for the first time.

11/3/16 9:05am EDT
Spark Therapeutics and Pfizer Announce Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels of Factor IX Activity

  • First seven participants, through a combined 103 weeks of observation as of Aug. 4, 2016,  did not need infusions of factor IX concentrates to prevent bleeding
  • Updated SPK-9001 data in hemophilia B to be presented at the Plenary Scientific Session at 58th American Society of Hematology Annual Meeting

11/2/16 6:45am EDT
Pfizer’s Prevenar 13® Receives Approval For Use in Infants and Children in China

  • Prevenar 13® is Approved to Help Protect Infants and Children Aged Six Weeks to Fifteen Months from Invasive Pneumococcal Disease

Pfizer China announced today that it has received approval from the Chinese Food and Drug Administration (CFDA) to market its pneumococcal 13-valent conjugate vaccine, Prevenar 13®, in China for active immunization for the prevention of invasive diseases (including bacteremic pneumonia, meningitis, septicemia, and bacteremia) caused by Streptococcus pneumoniae (S.

11/1/16 6:45am EDT
Pfizer Reports Third-Quarter 2016 Results

Please find Pfizer’s press release and associated financial tables, including reconciliations of certain GAAP reported to non-GAAP adjusted information, at the following hyperlink:
11/1/16 6:30am EDT
Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor

Company will record a charge to GAAP and Adjusted earnings in the fourth quarter of 2016 estimated to be approximately $0.04 per share


Pfizer Inc. announced today the discontinuation of the global clinical development program for bococizumab, its investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i). The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering agents, indicates that bococizumab is not likely to provide value to patients, physicians, or shareholders. As a result, Pfizer has decided to discontinue the development program, including the two ongoing cardiovascular outcome studies.

10/31/16 3:00am EDT
European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma

  • If approved, avelumab, an investigational anti-PD-L1 IgG1, could be the first treatment indicated for patients with metastatic Merkel cell carcinoma 
  • The Marketing Authorization Application is based on Phase II data from the JAVELIN Merkel 200 study demonstrating meaningful tumor responses in patients with metastatic disease that progressed after prior chemotherapy  
  • JAVELIN Merkel 200 is the largest reported anti-PD-L1/PD-1 antibody study in this patient population 

Merck KGaA, Darmstadt, 

10/21/16 11:55am EDT
FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced Prostate Cancer

- TERRAIN Trial Showed Improved Radiographic Progression-Free Survival with Enzalutamide Versus Bicalutamide in Men with Metastatic Castration-Resistant Prostate Cancer -

Astellas Pharma Inc. (TSE: 4503) and Pfizer Inc.

10/19/16 6:02pm EDT
CDC Advisory Committee on Immunization Practices Votes to Recommend New Dosing Schedule for Vaccination with TRUMENBA® (Meningococcal Group B Vaccine)

Recommendation provides updated guidance for administering a two- or a three-dose series

Pfizer Inc. (NYSE: PFE) announced today that the U.S.

10/19/16 8:00am EDT
Pfizer Awarded Grant to Evaluate Vaccine to Protect Newborns Against Group B Streptococcus Infection

  • Grant from the Bill & Melinda Gates Foundation will help advance potential new vaccine that could provide protection from debilitating infections before and shortly after birth
  • About 1 out of every 4 pregnant women carries group B Streptococcus bacteriai which could be passed from mother to baby during labor and birth
  • A severe, aggressive and potentially deadly infection, group B Streptococcus is a leading cause of life-threatening neonatal sepsis and meningitisii

Pfizer Inc.

10/17/16 4:05pm EDT
Pfizer Announces The U.S. Availability Of Biosimilar INFLECTRA® (infliximab-dyyb)

Company to Begin Shipping to Wholesalers in Late November, 2016

Pfizer Inc.

10/15/16 10:30am EDT
Pfizer to Present New Data on XELJANZ® (Tofacitinib Citrate) for Ulcerative Colitis at UEG Week 2016

Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being investigated in moderate to severe ulcerative colitis (UC), will be presented at the upcoming United European Gastroenterology Week (UEG Week 2016), October 15-19 in Vienna, Austria.

10/10/16 2:15am EDT
First Positive Phase 3 Results In Adjuvant Setting For Renal Cell Carcinoma Show SUTENT® (sunitinib) Extended Disease Free Survival After Surgical Removal

Late-breaking data to be presented at the ESMO 2016 Congress and Published in The New England Journal of Medicine

Pfizer Inc.

10/9/16 10:30am EDT
Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA® (axitinib) In Advanced Renal Cell Carcinoma (RCC)

  • Data From a Trial of INLYTA With Pembrolizumab Provides Additional Support for Novel Immunotherapy Combinations in RCC
  • Preliminary Results from an Ongoing Trial of INLYTA with Avelumab in RCC Were Also Presented

Pfizer Inc.

10/6/16 7:45am EDT
ICU Medical Inc. To Acquire The Hospira Infusion Systems Business From Pfizer Inc. For $1 Billion In Cash And Stock

The Addition of Hospira’s IV Pumps, Solutions, and Devices Business to ICU Medical’s Existing Portfolio Will Create a Leading Pure-Play Infusion Therapy Company
  • Creates an integrated pure-play infusion therapy company with focus and scale 
  • Combined business to compete in the US market with a unified organization and a complementary portfolio
  • Extends global reach for the combined company with direct operations in over 20 countries
  • Value-creating and risk mitigated deal structure
  • ICU Medical Inc. management conference call today at 8:00 am EST, details below


9/28/16 8:50am EDT
Pfizer Completes Acquisition of Medivation

  • Tender offer for all of the outstanding shares of Medivation common stock expired as scheduled one minute after 11:59 p.m., Eastern time, on September 27, 2016
  • Pfizer and Medivation begin joint operations on September 28, 2016
  • Combined expertise accelerates Pfizer’s leadership in Oncology, bringing much-needed new cancer treatments to patients
  • Expected to be immediately accretive to Pfizer’s Adjusted Diluted EPS upon closing, approximately $0.05 accretive in first full year after close with additional accretion and growth anticipated thereafter

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Medivation, Inc.(NASDAQ: MDVN).

9/28/16 6:00am EDT
Pfizer to Showcase Progress of Broad-Based Oncology Portfolio at European Society for Medical Oncology (ESMO) 2016 Congress

20 abstracts across multiple tumor types; unique mechanisms of action address the diverse needs of people living with cancer

New combination study data in renal cell carcinoma and first-in-human results for OX40 agonist provide new insights in immuno-oncology

Pfizer Inc. (NYSE:PFE) today announced that it will be presenting data from 20 abstracts, including three late-breakers, at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen from October 7-11, 2016. The presentations demonstrate progress addressing cancer’s complex challenges through our work across 11 tumor types and eight distinct mechanisms of action, including two immuno-oncology/targeted therapy combination studies in renal cell carcinoma (RCC).

9/26/16 6:45am EDT
Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation

  • Company to Continue to Operate as One Company with Two Distinct and Complementary Businesses to Retain Operating Strength and Financial Flexibility
  • Company Will Provide Enhanced Financial Transparency Beginning with First-Quarter 2017
  • Single-Company Structure Best Positions Pfizer to Deliver on Its Purpose to Deliver Medicines and Vaccines that Significantly Impact Patients’ Lives

Pfizer Inc. announced that, after an extensive evaluation, the company’s Board of Directors and Executive Leadership Team have determined the company is best positioned to maximize future shareholder value creation in its current structure and will not pursue splitting Pfizer Innovative Health and Pfizer Essential Health into two, separate publicly traded companies at this time.

9/23/16 8:30am EDT
Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation

Transaction expected to close in the Third-Quarter 2016

Pfizer Inc. (NYSE: PFE) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended has expired with respect to Pfizer’s pending acquisition of Medivation, Inc. (NASDAQ: MDVN).

Pfizer now expects to complete the acquisition in the Third-Quarter 2016. The closing of the tender offer remains subject to other customary closing conditions, including the tender of a majority of the outstanding shares of Medivation common stock.

About Pfizer:

9/22/16 11:56am EDT
Pfizer Declares 30-Cent Fourth-Quarter 2016 Dividend

The board of directors of Pfizer Inc. today declared a 30-cent fourth-quarter 2016 dividend on the company’s common stock, payable December 1, 2016, to shareholders of record at the close of business on November 11, 2016.

9/20/16 10:00am EDT
Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, November 1, 2016. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2016 Performance Report, to be issued that morning.